Profile data is unavailable for this security.
About the company
Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.
- Revenue in HKD (TTM)904.32m
- Net income in HKD571.07m
- Incorporated2016
- Employees210.00
- LocationHbm Holdings LtdLevel 54, Hopewell Centre, 183Queen's Road East, Wan ChaiSUZHOU ChinaCHN
- Websitehttps://www.harbourbiomed.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tong Ren Tang Technologies Co Ltd | 7.86bn | 488.40m | 5.66bn | 3.89k | 11.59 | 0.6858 | 4.58 | 0.7202 | 0.3813 | 0.3813 | 6.14 | 6.44 | 0.482 | 0.8615 | 6.00 | 1,969,535.00 | 5.47 | 7.44 | 8.57 | 12.07 | 39.82 | 42.21 | 11.34 | 15.10 | 2.79 | -- | 0.1913 | 39.34 | 7.18 | 10.15 | -11.59 | 4.55 | -8.30 | 3.37 |
| Ocumension Therapeutics | 615.11m | -281.98m | 5.71bn | 505.00 | -- | 1.38 | -- | 9.28 | -0.3764 | -0.3764 | 0.8214 | 5.08 | 0.1571 | 4.30 | 3.35 | 1,257,900.00 | -7.20 | -24.03 | -7.62 | -25.71 | 42.58 | 58.38 | -45.84 | -400.90 | 4.86 | -- | 0.0223 | -- | 69.38 | 365.95 | 29.36 | -- | 213.01 | -- |
| Beijing Tong Ren Tang Chinese Medicine | 1.71bn | 515.36m | 7.53bn | 789.00 | 14.62 | 1.87 | 12.00 | 4.41 | 0.6157 | 0.6157 | 2.04 | 4.81 | 0.3878 | 0.4134 | 4.92 | 2,185,246.00 | 12.14 | 15.34 | 13.34 | 17.17 | 63.00 | 68.94 | 31.29 | 39.16 | 11.43 | -- | 0.0327 | 52.52 | 5.69 | 2.38 | -7.42 | -2.09 | 20.50 | 8.76 |
| China Shineway Pharmaceutical Group Ltd | 3.78bn | 936.99m | 8.10bn | 2.87k | 7.89 | 0.9164 | 10.39 | 2.14 | 1.24 | 1.24 | 5.01 | 10.68 | 0.3299 | 1.15 | 3.81 | 1,174,894.00 | 8.17 | 8.29 | 10.75 | 10.38 | 73.36 | 74.83 | 24.77 | 18.67 | 3.39 | -- | 0.0419 | 37.49 | -16.35 | 6.90 | -13.35 | 10.80 | 8.92 | 19.39 |
| CStone Pharmaceuticals | 229.08m | -426.61m | 8.72bn | 93.00 | -- | 22.63 | -- | 38.08 | -0.3273 | -0.3273 | 0.1768 | 0.2612 | 0.1487 | 1.38 | 1.68 | 1,696,892.00 | -27.69 | -39.13 | -54.45 | -60.19 | -12.18 | 66.69 | -186.23 | -170.86 | 1.20 | -29.83 | 0.554 | -- | -12.21 | -- | 75.16 | -- | -- | -- |
| SSY Group Ltd | 4.58bn | 658.92m | 8.76bn | 5.70k | 13.54 | 1.23 | 7.79 | 1.91 | 0.223 | 0.223 | 1.55 | 2.46 | 0.3616 | 2.27 | 2.11 | 751,065.60 | 5.27 | 9.41 | 6.34 | 12.43 | 42.68 | 56.47 | 14.58 | 17.65 | 2.40 | 14.91 | 0.346 | 42.91 | -10.67 | 4.49 | -19.53 | -1.36 | -8.36 | 9.73 |
| Hbm Holdings Ltd | 904.32m | 571.07m | 10.28bn | 210.00 | 15.96 | 4.25 | 17.19 | 11.37 | 0.7405 | 0.7405 | 1.14 | 2.78 | 0.3856 | 6.32 | 32.64 | 5,796,901.00 | 24.77 | -42.87 | 30.77 | -53.24 | 92.95 | 96.12 | 64.25 | -292.58 | 6.02 | 28.63 | 0.1857 | -- | -57.43 | 47.71 | -87.81 | -- | -55.31 | -- |
| China Traditional Chinese Med Hldg CoLtd | 17.63bn | -299.61m | 10.32bn | 15.58k | -- | 0.4408 | 11.36 | 0.5854 | -0.0595 | -0.0595 | 3.50 | 4.65 | 0.4326 | 1.59 | 1.71 | 1,052,615.00 | -0.93 | 3.48 | -1.42 | 5.24 | 47.66 | 54.69 | -2.15 | 7.39 | 1.51 | 9.55 | 0.1333 | 21.27 | -8.90 | 2.89 | -95.79 | -49.14 | -15.28 | -48.82 |
| Luye Pharma Group Ltd | 6.98bn | 449.06m | 10.79bn | 5.12k | 22.62 | 0.611 | 6.74 | 1.55 | 0.1194 | 0.1194 | 1.86 | 4.42 | 0.2083 | 2.42 | 2.37 | 1,354,931.00 | 1.91 | 1.98 | 3.26 | 3.16 | 66.85 | 68.37 | 9.15 | 8.04 | 1.24 | 2.35 | 0.4227 | 0.00 | -1.33 | -0.9503 | -11.40 | -19.50 | -10.95 | -- |
| Fujian Haixi Pharmaceuticals Co Ltd | -100.00bn | -100.00bn | 10.92bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 47.39 | -- | 15.86 | -- | -- | -- |
| Guangzhou Innogen Pharmaceutl Grp Co Ltd | -100.00bn | -100.00bn | 12.79bn | 105.00 | -- | 15.05 | -- | -- | -- | -- | -- | 1.84 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.39 | -- | 0.0769 | -- | -- | -- | 76.18 | -- | -- | -- |
| Everest Medicines Ltd | 963.07m | -745.25m | 13.88bn | 722.00 | -- | 2.90 | -- | 14.41 | -2.31 | -2.31 | 2.98 | 13.55 | 0.1684 | 13.97 | 3.04 | 1,448,222.00 | -13.03 | -29.28 | -14.21 | -31.67 | 69.92 | -- | -77.38 | -1,040.86 | 5.43 | -- | 0.1577 | -- | 461.16 | -- | -23.32 | -- | 16.96 | -- |
| Sihuan Pharmaceutical Holdings Group Ltd | 2.37bn | -91.22m | 15.00bn | 2.77k | -- | 3.04 | -- | 6.32 | -0.0098 | -0.0098 | 0.2572 | 0.5396 | 0.1894 | 1.49 | 3.86 | 889,784.80 | -3.05 | -3.60 | -5.01 | -5.05 | 66.29 | 73.13 | -16.08 | -19.74 | 1.61 | -1.36 | 0.1606 | -- | 2.18 | -7.96 | -301.10 | -- | -20.58 | 3.60 |
Data as of Feb 16 2026. Currency figures normalised to Hbm Holdings Ltd's reporting currency: Hong Kong Dollar HKD
14.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GIC Pte Ltd. (Investment Management)as of 14 Jan 2026 | 71.95m | 8.05% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 22.47m | 2.51% |
| Principal Asset Management Co. (Asia) Ltd.as of 30 Jun 2025 | 10.17m | 1.14% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 6.90m | 0.77% |
| Dimensional Fund Advisors LPas of 30 Nov 2025 | 4.95m | 0.55% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 2.93m | 0.33% |
| HSBC Global Asset Management (Hong Kong) Ltd.as of 31 Dec 2025 | 2.70m | 0.30% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 1.91m | 0.21% |
| Charles Schwab Investment Management, Inc.as of 05 Feb 2026 | 1.25m | 0.14% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2025 | 1.24m | 0.14% |
More ▼
Data from 30 Jun 2025 - 06 Feb 2026Source: FactSet Research Systems Inc.
